WO2012173226A1 - Préparation pharmaceutique contenant un sel d'acide polystyrènesulfonique - Google Patents

Préparation pharmaceutique contenant un sel d'acide polystyrènesulfonique Download PDF

Info

Publication number
WO2012173226A1
WO2012173226A1 PCT/JP2012/065354 JP2012065354W WO2012173226A1 WO 2012173226 A1 WO2012173226 A1 WO 2012173226A1 JP 2012065354 W JP2012065354 W JP 2012065354W WO 2012173226 A1 WO2012173226 A1 WO 2012173226A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical preparation
water
preparation according
mass
sugar
Prior art date
Application number
PCT/JP2012/065354
Other languages
English (en)
Japanese (ja)
Inventor
安幸 平
和之 垣見
圭助 足立
倫 野田
康義 清水
Original Assignee
株式会社 三和化学研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社 三和化学研究所 filed Critical 株式会社 三和化学研究所
Priority to JP2013520598A priority Critical patent/JP5940530B2/ja
Publication of WO2012173226A1 publication Critical patent/WO2012173226A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Definitions

  • Polystyrene sulfonate which is a cation exchange resin, is an effective therapeutic agent for hyperkalemia patients and performs extracorporeal potassium excretion by ion exchange in the intestine.
  • Polystyrene sulfonate is a powdery resin that is almost insoluble in water, and even when suspended and taken with water, it feels uncomfortable as if it bites sand. When taken as it is without suspending, the saliva is sucked in the mouth and cannot be swallowed. Furthermore, polystyrene sulfonate has a problem that the daily dose is large (5 to 15 g / day).
  • polystyrene sulfonate is a preparation that is very difficult to take
  • various devices have been conventionally made.
  • a powder or a dry syrup produced by mixing a polystyrene sulfonate with a sweetener and / or a sour agent Patent Document 1
  • a polystyrene sulfonate and a gelling agent CMC-Na
  • Document 2 polystyrene sulfonic acid polymer tablet containing binder and moisture
  • Patent Document 4 polystyrene sulfonic acid polymer tablet containing binder and moisture
  • Patent Document 4 polystyrene sulfonic acid polymer tablet containing binder and moisture
  • Patent Document 4 polystyrene sulfonic acid polymer tablet containing binder and moisture
  • Patent Document 4 Patent Document 4
  • gel composition Patent Document 6, Patent Document 7, Patent Document 8
  • powders, dry syrups, tablets, and the like have not yet been improved in ingestibility when
  • Japanese Patent Laid-Open No. 11-292769 Japanese Patent No. 3596742 Japanese translation of PCT publication 2010-502709 Japanese Patent No. 3390455 JP 2004-231548 A International Publication No. 98/058654 JP 2000-325031 A Japanese Patent Laid-Open No. 2001-181212 International Publication No. 2006/129668
  • an object of the present invention is to provide a polystyrene sulfonate-containing pharmaceutical preparation containing a water-absorbing feeling and a burning sensation when taken and having a small amount of excipient.
  • the present inventors have intensively studied based on the idea that a surface coating is useful in order to improve the difficulty of taking polystyrene sulfonate, such as water absorption and burning sensation. And, by coating the surface with a combination of (a) a water-soluble polymer or a water-insoluble polymer and (b) a sugar or sugar alcohol, the bad feeling of taking peculiar to polystyrene sulfonate is significantly suppressed, and The inventors have found that the amount of excipient can be reduced and have completed the present invention.
  • the main configuration of the present invention is as follows. (1) a core granule containing polystyrene sulfonate and a binder, and one or more coating layers formed on the surface of the core granule, wherein the coating layer is at least (a) a water-soluble polymer Or a pharmaceutical preparation containing polystyrene sulfonate as an active ingredient, which contains a water-insoluble polymer and (b) a sugar or a sugar alcohol. (2) The pharmaceutical preparation according to (1), wherein the polystyrene sulfonate is 65 to 95% by mass with respect to the whole pharmaceutical preparation.
  • the water-soluble polymer is a cellulose derivative, pullulan, polyvinyl pyrrolidone, vinyl pyrrolidone / vinyl acetate copolymer, polyvinyl alcohol-polyethylene glycol graft copolymer, polyvinyl alcohol, polyethylene glycol, methacrylic acid copolymer,
  • (13) The pharmaceutical preparation according to (12), wherein the water-soluble polymer is a cellulose derivative, and the viscosity of a 2% by mass aqueous solution of the cellulose derivative at 20 ⁇ 0.1 ° C.
  • the water-insoluble polymer is ethyl cellulose, a methacrylic acid copolymer, and a combination thereof.
  • sugar or sugar alcohol is selected from the group consisting of mannitol, sorbitol, xylitol, erythritol, trehalose, sucrose, sucralose, lactose, lactitol, powdered reduced maltose syrup, glucose, fructose, and dextrin.
  • FIG. 1 It is a figure which shows an example of a water absorption measuring apparatus. Symbols in the figure are: (a) substance to be measured; (b) filter paper; (c) metal wire mesh; (d) silicon tube; (e) three-way stopcock; (f) syringe; (g) female pipette; (h) Means a camera for recording the state of a substance to be measured; (i) a camera for recording water absorption; (j) purified water kept at 37 ° C .; and (k) a water bath at 37 ° C. It is a figure which shows a water absorption amount measurement result. It is a figure which shows the calorific value measurement result.
  • the pharmaceutical preparation according to the present invention has core granules containing polystyrene sulfonate, and (a) a coating layer made of a combination of a water-soluble polymer or water-insoluble polymer and (b) a sugar or a sugar alcohol.
  • a pharmaceutical preparation characterized by By coating the core granules with the above (a) and (b), the conflicting problems of improving the feeling of taking and reducing the excipient can be solved.
  • Polystyrene sulfonate is a cation exchange resin. Specific examples include calcium polystyrene sulfonate and sodium polystyrene sulfonate.
  • the 50% particle size of the polystyrene sulfonate when the particle size of the powder is measured by the laser diffraction method is preferably 5 to 100 ⁇ m, more preferably 20 to 60 ⁇ m. If the 50% particle size of polystyrene sulfonate is too large, it will feel rough in the oral cavity. On the other hand, if it is too small, it will remain in the oral cavity for a long time, resulting in a poor feeling of taking.
  • the 50% particle size refers to the particle size at the time when the cumulative frequency of occurrence is 50% when the particle size is measured by laser diffraction method after being dispersed in ethanol.
  • the core granule is a core granule containing polystyrene sulfonate and a binder, and can be produced according to a known method.
  • polystyrene sulfonate can be kneaded with a binder and formed into a spherical shape by a spherical granulator.
  • the solvent for kneading include water, ethanol, and a mixture thereof, and those skilled in the art can appropriately select them.
  • the binder is preferably one that hardly undergoes ion exchange with calcium or sodium polystyrene sulfonate as an active ingredient when the pharmaceutical preparation is dissolved.
  • dextrin crystalline cellulose, hydroxypropylcellulose (HPC), ethylcellulose (EC), mannitol, polyvinylpyrrolidone (PVP, povidone), hydroxypropylmethylcellulose (HPMC), low substituted hydroxypropylcellulose (L-HPC), corn starch , Methyl cellulose, purified white sugar, reduced maltose water candy, reduced maltose and the like, and one or more selected from these can be used in appropriate combination.
  • the shape of the core granule is not particularly limited, but it is desirable that it is spherical when a more uniform coating layer is desired.
  • the core granule can be performed by a method such as centrifugal rolling granulation method, rolling fluid granulation method, fluid granulation method, stirring granulation method, extrusion granulation method or the like.
  • the extrusion granulation method is preferable. According to this, the specific volume of the nuclear granule can be reduced.
  • the production apparatus is not limited. For example, if a composite granulator such as a centrifugal rolling granulation coating machine is used, the operability is good and the production can be efficiently performed. Further, following the extrusion granulation method, it can also be produced by spherical granulation using a spherical granulator.
  • the particle diameter of the core granule is preferably less than 2 mm, and more preferably less than 1.4 mm when sieving using a sieve having openings of 0.25 mm, 1.4 mm, and 2 mm.
  • the particle diameter of the core granule is preferably less than 2 mm, and more preferably less than 1.4 mm when sieving using a sieve having openings of 0.25 mm, 1.4 mm, and 2 mm.
  • the particle size of the core granule is too small, the surface area per unit mass will be larger than that of the larger particle size, and it will be more difficult to suppress water absorption and burning sensation. It is preferable to reduce the proportion of granules as much as possible.
  • the texture becomes worse it is preferable to reduce the proportion of core granules having a particle size of 2.0 mm or more as much as possible.
  • a coating layer is formed on the surface of the core granule of the present invention.
  • the coating layer comprises a combination of at least (a) a water-soluble polymer or a water-insoluble polymer and (b) a sugar or a sugar alcohol.
  • the coating layer may be one layer or two or more layers.
  • One or more coating layers containing (a) and (b) may be formed, and the coating layer containing (b) is further formed on the coating layer (first layer) containing (a).
  • a second layer) may be formed.
  • the coating layer is preferably a single layer.
  • the (a) water-soluble polymer or water-insoluble polymer is usually 0.5 to 24.5% by mass, preferably 0.5 to 20% by mass, more preferably 0.5 to 10% by mass, still more preferably 0.5 to Add 5% by weight.
  • the amount of polystyrene sulfonate is usually 0.5 to 30% by mass, preferably 0.5 to 22% by mass, more preferably 0.5 to 15% by mass, and still more preferably 0.5 to 6% by mass.
  • the specific addition amount is usually 0.025 to 1.5 g, preferably 0.025 to 1.1 g, more preferably 0.025 to 0.75 g, and still more preferably 0.025 to 0.3 g with respect to 5 g of polystyrene sulfonate.
  • cellulose derivatives examples include hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), methylcellulose, hydroxypropylmethylcellulose phthalate, hydroxyethylcellulose, and hydroxypropylmethylcellulose acetate succinate.
  • HPMC hydroxypropylmethylcellulose
  • HPC hydroxypropylmethylcellulose
  • HPC hydroxypropylcellulose
  • HPC hydroxypropylcellulose
  • methylcellulose hydroxypropylmethylcellulose phthalate
  • hydroxyethylcellulose hydroxypropylmethylcellulose acetate succinate
  • cellulose derivatives there are those having different viscosities when dissolved in water or ethanol, but those having a viscosity of 2 to 15000 mPa ⁇ m at 20 ⁇ 0.1 ° C. are preferred, and 2 to 12000 mPa ⁇ s. -M is more preferable. If the viscosity is too high, coating becomes difficult, and if the viscosity is too low, the storage stability of the
  • water-soluble polymers hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, polyvinylpyrrolidone, pullulan, aminoalkyl methacrylate copolymer, methacrylic acid copolymer, polyvinyl alcohol / acrylic acid / methyl methacrylate copolymer, And a combination of one or more selected from sucrose fatty acid esters, more preferably hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, pullulan, polyvinylpyrrolidone, and polyvinyl alcohol / acrylic acid / methyl methacrylate copolymer
  • sucrose fatty acid esters more preferably hydroxypropylmethylcellulose, hydroxypropylcellulose, methylcellulose, pullulan, polyvinylpyrrolidone, and polyvinyl alcohol / acrylic acid / methyl methacrylate copolymer
  • sodium polyacrylate, croscarmellose sodium, carboxymethyl starch sodium, and carmellose calcium or carmellose sodium ion exchange occurs with calcium or sodium polystyrene sulfonate as an active ingredient when dissolved, This is not preferable because the calcium or sodium content in the active ingredient changes and causes a difference in potassium exchange capacity.
  • the (b) sugar or sugar alcohol is usually added in an amount of 0.5 to 24.5% by mass, preferably 1 to 20% by mass, more preferably 1.5 to 10% by mass, based on the whole pharmaceutical preparation.
  • the polystyrene sulfonate is usually added in an amount of 0.5 to 30% by mass, preferably 1 to 25% by mass, more preferably 2 to 15% by mass.
  • the specific addition amount is usually 0.025 to 1.5 g, preferably 0.05 to 1.25 g, more preferably 0.10 to 0.75 g based on 5 g of polystyrene sulfonate.
  • sorbitol, mannitol, erythritol, sucralose, and lactose are preferable.
  • the sugar or sugar alcohol one or more selected from these can be used alone or in appropriate combination.
  • an artificial sweetener such as saccharin
  • a glycogenic amino acid such as glycine
  • Examples of the combination of (a) water-soluble polymer or water-insoluble polymer and (b) sugar or sugar alcohol used for the coating layer include the following combinations.
  • sorbitol (x), mannitol (xi), erythritol (xii), sucralose (xiii), lactose (xiv), xylitol (xv), trehalose (xvi), lactitol (Xvii), sucrose (xviii), powdered reduced maltose starch syrup (xix), glucose (xx), fructose (xxi) and dextrin (xxii) are as follows.
  • the total of (a) water-soluble polymer or water-insoluble polymer and (b) sugar or sugar alcohol contained in the coating layer is 1 to 30% by mass, preferably 2 to 25% by mass, based on the whole pharmaceutical preparation, More preferably, it is 3 to 20% by mass.
  • the ratio of (a) :( b) is 1:20 to 20: 1, preferably 1:12 to 4: 1, more preferably 1:10 to 2: 1.
  • coating layer on the surface of the core granule When applying a coating layer on the surface of the core granule, use a production apparatus such as a fluid granulator or a tumbling granulator, and (a) a water-soluble polymer or water-insoluble polymer and (b) a sugar or sugar alcohol. It can coat
  • a person skilled in the art can appropriately set the optimum concentration of the coating liquid.
  • coating in the present invention means a “coating” state temporarily covered with a liquid substance, a “coating” state that is uniform throughout, or a “coating” state that is non-uniform throughout, and covers the whole. As well as those that partially cover.
  • the surface coating of the core granule is performed with the combination of the present invention, it is possible to suppress the poor feeling of taking the polystyrene sulfonate even if it is not uniformly coated. In other words, it is possible to suppress the poor feeling of taking the polystyrene sulfonate even if the composition and thickness mask the core granules.
  • the polystyrene sulfonate as an active ingredient is contained in an amount of 65 to 95% by mass, preferably 70 to 93% by mass, more preferably 75 to 90% by mass, based on the whole pharmaceutical preparation.
  • the composition ratio of active ingredient: excipient is 95: 5 to 65:35, preferably in the range of 93: 7 to 70:30, 90:10 to 75:25 More preferably, it is in the range.
  • it is possible to suppress the inferior taking feeling peculiar to polystyrene sulfonates in an amount smaller than the amount of excipients usually required for ensuring dosing.
  • the content rate (mass%) of a polystyrene sulfonate is reduced too much, it will increase the volume of the pharmaceutical formulation to take more than necessary, and will become a pharmaceutical formulation which is hard to take.
  • the particle diameter of the pharmaceutical preparation (coating preparation) of the present invention is less than 30% by mass of particles less than 0.5 mm when sieving is performed using a sieve having openings of 0.5 mm, 1.4 mm, and 2.0 mm. It is preferable that Moreover, it is preferable not to contain particles of 2.0 mm or more, and particles of 1.4 mm or more and less than 2.0 mm are preferably less than 20% by mass of the whole pharmaceutical preparation. Accordingly, particles less than 0.5 mm are less than 30% by mass of the whole pharmaceutical preparation, and particles of 1.4 mm or more and less than 2.0 mm are less than 20% by mass of the whole pharmaceutical preparation, and do not contain particles of 2.0 mm or more.
  • the pharmaceutical preparation (coating preparation) of the present invention is particularly preferred.
  • the pharmaceutical preparation (coating preparation) of the present invention in which particles of less than 0.5 mm are less than 30% by mass of the whole pharmaceutical preparation and particles of 1.4 mm or more are less than 20% by mass of the whole pharmaceutical preparation, This is particularly preferable.
  • the ratio of the coating preparation having a particle size of less than 0.25 mm increases, it becomes more difficult to suppress the water absorption feeling and the burning feeling, and when the ratio of the coating preparation having a particle diameter of 1.4 mm or more increases, the texture becomes worse.
  • the pharmaceutical preparation of the present invention can be further added with commonly used sweeteners, colorants, fragrances, preservatives, fungicides, surfactants and the like as necessary. These can be added to the core granule part or the coating layer part.
  • the calorific value is preferably a temperature increase of less than 5 ° C., more preferably a temperature increase of less than 3 ° C. 10 seconds after administration into the oral cavity.
  • a water absorption measuring device was created and the amount of water absorbed by the target substance was measured.
  • a schematic diagram of the water absorption measuring device is shown in FIG.
  • the measurement target substance was placed on a wet filter paper, and the change over time in the amount of purified water adjusted to 37 ° C. from the bottom surface of the measurement target substance was measured. That is, first, (e) is operated so that water passes from (j) to (f), and (f) is filled with purified water. Next, (e) was operated so that (f) to (b) could pass water, and (b) was sufficiently wetted.
  • (d) was extracted from (j), and (e) was operated so that (d) to (f) could pass through, so that the surface of the purified water was adjusted to the zero point on the scale of (g). Finally, operate (e) so that (b) passes through (b) and place (a) on (b) .At the same time, (h) changes the state of (a) to (i). The position of the water surface in (g) was recorded simultaneously with the elapsed time. Based on the elapsed time and water surface position information recorded in (i), the water absorption amount in (a) was calculated.
  • Test method for sensory test 1 One person in charge of the test performed a dosing test. An amount corresponding to 5 g as a cation exchange resin for each granule was included in the mouth without suspending, and its water absorption feeling and burning feeling were evaluated.
  • Test method for sensory test 2 A sensory test was conducted by 14 panelists aged 49 to 62 years. Each paneler contains 5 g of the cation exchange resin for each granule in the mouth without suspending it, then take 50 mL or less of water as needed by each paneler, in order of good feeling. Ranking.
  • Test method for sensory test 3 Sensory tests were conducted by nine panelists aged 25 to 35 years. Each paneler should take an amount equivalent to 5 g as a cation exchange resin for each granule in the mouth without suspending it, and then take 50 mL of water in three divided doses, and rank them in the order of good feeling. It was.
  • Test method for sensory test 4 Sensory tests were conducted by 6 panelists aged 24 to 29 years. Each paneler should take the amount corresponding to 5 g as a cation exchange resin for each granule in the mouth without suspending it, and then take 50 mL of water in 3 divided doses. A score was assigned for each granule, with a score of 1 point when the feeling of administration was very poor.
  • Test method for sensory test 5 A sensory test was conducted by six panelists aged 25 to 36 years. The same method as in sensory test 4 was performed.
  • the resulting kneaded product is extruded by an extrusion granulator (DOME GRAN; manufactured by Fuji Powder) equipped with a 1 mm or 1.5 mm screen (dome die), followed by a spherical granulator (Malmerizer; Fuji Powder) And then dried with a fluidized bed granulator (FLO; manufactured by Freund Corporation) to prepare core granules.
  • OTYE GRAN extrusion granulator
  • Malmerizer Fuji Powder
  • FLO fluidized bed granulator
  • the obtained nuclear granules were sieved using a sieve having an aperture of 1.4 mm or 2 mm, and the nuclear granules having passed through the sieve having an aperture of 2 mm or an aperture of 1.4 mm were used for coating.
  • sieving is performed using a sieve with an opening of 0.25 mm and an opening of 2 mm, and the core granules that pass through the sieve with an opening of 2 mm and do not pass through the sieve with an opening of 0.25 mm are coated. Used for.
  • the coating liquid 1 was prepared by dissolving the excipient described in the coating layer or the first layer of the coating layer in water. Using a fluidized bed granulator (FLO; manufactured by Freund Sangyo Co., Ltd.), the core granule was coated with the coating liquid 1 and then dried to obtain a coated granule (one layer).
  • the coating liquid 2 was prepared by dissolving the excipient described in the second layer of the coating layer in water, and using a fluidized bed granulator, the coated granules The coating solution (1 layer) was further coated with the coating liquid 2 and dried to obtain a coated granule (2 layers).
  • Examples 1 to 11 and Examples 14 to 43 which were surface-coated with a combination of (a) a water-soluble polymer, and (b) a sugar or sugar alcohol, each had a strong water absorption feeling immediately after taking and The burning sensation was suppressed.
  • Examples 12 and 13 which were surface coated with a combination of (a) a water-insoluble polymer and (b) a sugar or sugar alcohol. This was the same whether the surface coating was one layer or two layers.
  • Comparative Examples 1 to 3 in which no surface coating was applied all the formulations had a feeling of intense water absorption and a burning sensation similar to the case where the cation exchange resin was taken as it was immediately after taking it. I felt.
  • Comparative Example 2 and Comparative Example 3 (b) sugar or sugar alcohol was further added to the core granule part, but still felt water absorption and burning. From this, it was shown that the surface coating of the core granule is necessary to suppress the intense water absorption and burning feeling immediately after taking.
  • Comparative Example 4 in which (a) the surface coating of the water-soluble polymer alone was applied a strong water absorption feeling and a burning sensation were felt, and further, roughness and stickiness were felt.

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour but de proposer une préparation pharmaceutique contenant un sel d'acide polystyrènesulfonique, qui a une sensation réduite d'absorption d'eau et une sensation réduite en brûlure lors d'une ingestion par comparaison avec des produits classiques et qui contient un excipient dans une quantité réduite. A cet effet, l'invention propose une préparation pharmaceutique contenant un sel d'acide polystyrènesulfonique comme ingrédient actif, qui comprend des granulés de noyau comprenant chacun le sel d'acide polystyrènesulfonique et un liant, chacun des granulés de noyau ayant au moins une couche de revêtement formée sur la surface de celui-ci et la couche de revêtement comprenant au moins (a) un polymère soluble dans l'eau ou un polymère insoluble dans l'eau et (b) un sucre ou un alcool de sucre.
PCT/JP2012/065354 2011-06-17 2012-06-15 Préparation pharmaceutique contenant un sel d'acide polystyrènesulfonique WO2012173226A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013520598A JP5940530B2 (ja) 2011-06-17 2012-06-15 ポリスチレンスルホン酸塩含有医薬製剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011-134908 2011-06-17
JP2011134908 2011-06-17

Publications (1)

Publication Number Publication Date
WO2012173226A1 true WO2012173226A1 (fr) 2012-12-20

Family

ID=47357204

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/065354 WO2012173226A1 (fr) 2011-06-17 2012-06-15 Préparation pharmaceutique contenant un sel d'acide polystyrènesulfonique

Country Status (2)

Country Link
JP (1) JP5940530B2 (fr)
WO (1) WO2012173226A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018131716A1 (fr) * 2017-01-16 2018-07-19 株式会社カネカ Pâte, confiserie cuite, composition pharmaceutique et leur procédé de production
WO2018131717A1 (fr) * 2017-01-16 2018-07-19 株式会社カネカ Pâte, confiserie cuite, composition pharmaceutique et leur procédé de production

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05201855A (ja) * 1992-01-29 1993-08-10 Ss Pharmaceut Co Ltd 顆粒剤
WO1999020247A1 (fr) * 1997-10-16 1999-04-29 Sanwa Kagaku Kenkyusho Co., Ltd. Preparation de gel contenant des sulfonates de polystyrene
JPH11292769A (ja) * 1998-04-10 1999-10-26 Toyo Seiyaku Kasei Kk 高カリウム血症改善剤組成物
JP2000103739A (ja) * 1998-07-31 2000-04-11 Nikken Chem Co Ltd 陽イオン交換樹脂製剤
JP2000516222A (ja) * 1996-08-15 2000-12-05 ロザン ファルマ ゲゼルシャフトミットベシュレンクテル ハフツング 嚥下が容易な経口医薬組成物
WO2003026619A1 (fr) * 2001-09-26 2003-04-03 Kyowa Hakko Kogyo Co., Ltd. Granules presentant des proprietes de dosage ameliorees
WO2006129668A1 (fr) * 2005-05-30 2006-12-07 Meiji Seika Kaisha, Ltd. Pilule enrobee de sucre
JP2007284397A (ja) * 2006-04-18 2007-11-01 Toshie Yasuda 機能性組成物の製造方法
JP2011063627A (ja) * 2010-08-31 2011-03-31 Kyowa Hakko Kirin Co Ltd 苦味を呈する薬物を含有する顆粒および口腔内崩壊錠

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05201855A (ja) * 1992-01-29 1993-08-10 Ss Pharmaceut Co Ltd 顆粒剤
JP2000516222A (ja) * 1996-08-15 2000-12-05 ロザン ファルマ ゲゼルシャフトミットベシュレンクテル ハフツング 嚥下が容易な経口医薬組成物
WO1999020247A1 (fr) * 1997-10-16 1999-04-29 Sanwa Kagaku Kenkyusho Co., Ltd. Preparation de gel contenant des sulfonates de polystyrene
JPH11292769A (ja) * 1998-04-10 1999-10-26 Toyo Seiyaku Kasei Kk 高カリウム血症改善剤組成物
JP2000103739A (ja) * 1998-07-31 2000-04-11 Nikken Chem Co Ltd 陽イオン交換樹脂製剤
WO2003026619A1 (fr) * 2001-09-26 2003-04-03 Kyowa Hakko Kogyo Co., Ltd. Granules presentant des proprietes de dosage ameliorees
WO2006129668A1 (fr) * 2005-05-30 2006-12-07 Meiji Seika Kaisha, Ltd. Pilule enrobee de sucre
JP2007284397A (ja) * 2006-04-18 2007-11-01 Toshie Yasuda 機能性組成物の製造方法
JP2011063627A (ja) * 2010-08-31 2011-03-31 Kyowa Hakko Kirin Co Ltd 苦味を呈する薬物を含有する顆粒および口腔内崩壊錠

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SADAKO TOYOGUCHI ET AL.: "Ko Kalium Kessho Kaizenzai Kayexalate no Toyo Hoho no Kufu", IYAKU NO MON, vol. 31, no. 3, 1 June 1991 (1991-06-01), pages 50 - 55 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018131716A1 (fr) * 2017-01-16 2018-07-19 株式会社カネカ Pâte, confiserie cuite, composition pharmaceutique et leur procédé de production
WO2018131717A1 (fr) * 2017-01-16 2018-07-19 株式会社カネカ Pâte, confiserie cuite, composition pharmaceutique et leur procédé de production

Also Published As

Publication number Publication date
JPWO2012173226A1 (ja) 2015-02-23
JP5940530B2 (ja) 2016-06-29

Similar Documents

Publication Publication Date Title
KR100391104B1 (ko) 생체 이용율이 높은 페노피브레이트 제약학적 조성물과 그의제조방법
JP4098620B2 (ja) 抗結核剤の新規な医薬組成物及びその調製方法
US8968777B2 (en) Tranexamic acid formulations with reduced adverse effects
JP4638964B2 (ja) プロトンポンプ阻害剤およびｎｓａｉｄからなる経口用医薬剤形
JP3265680B2 (ja) 経口製剤用組成物
JP4439499B2 (ja) アムロジピン含有粒子およびそれからなる口腔内崩壊錠
JPH0251402B2 (fr)
WO2001022791A2 (fr) Compositions a liberation regulee contenant de la nimesulide
US20100047343A1 (en) Multiparticulate formulation having tramadol in immediate and controlled release form
JP5205053B2 (ja) トラネキサム酸製剤
JPH0625064B2 (ja) 制御放出塩化カリウム
JPS6248618A (ja) 徐放性製剤およびその製造法
JP2008524317A (ja) 腸溶コーティングされたアジスロマイシン多粒子
JP2004507487A (ja) 腸疾患治療薬
JP7336388B2 (ja) 錠剤及びその製造方法
JP5940530B2 (ja) ポリスチレンスルホン酸塩含有医薬製剤
EP3020416A1 (fr) Comprimé à désagrégration ultrarapide et sa méthode de fabrication
JP5876418B2 (ja) 口腔内崩壊錠剤
JP7336187B2 (ja) 多層構造を有する粒子状医薬組成物
TW201315462A (zh) 異丁苯丙酸可嚼錠
JP5828280B2 (ja) 錠剤及びその製造方法
JP2005139086A (ja) 速崩壊製剤
JP2018083809A (ja) シロドシン含有粒子の製造方法及びシロドシン含有口腔内崩壊錠の製造方法
JP2010001242A (ja) レバミピド固形製剤及びその製造方法
JPH11349473A (ja) 味マスキング医薬製剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12801308

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
ENP Entry into the national phase

Ref document number: 2013520598

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12801308

Country of ref document: EP

Kind code of ref document: A1